Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $2.02, $1.32 better than the analyst estimate of $0.70. Revenue for the quarter came in at $611.09 million versus the consensus estimate of $532.86 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.